Previous studies demonstrated that the anti-CD3 monoclonal antibody otelixizumab , administered at a total dose of 48-64 mg , can slow the loss of C-peptide in recent-onset type 1 diabetes patients , with frequent reactivation of Epstein Barr virus ( EBV ) .